维京治疗公司(Viking Therapeutics,代码VKTX)今日盘中股价大跌9.91%,引发市场广泛关注。
公司公布财报数据令投资者失望。每股亏损0.32美元,高于预期0.28美元,净亏损比去年同期扩大28%至3540万美元。研发费用大幅上升是亏损扩大的主因,包括临床试验费用及候选药物制造成本增加。
更令投资者担忧的是,公司实验性肥胖症药物VK2735试验最新进展只是增量,未达市场预期。在此背景下,投资者通过抛售来表达对公司前景的担忧,导致股价暴跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.